Literature DB >> 28168963

Ten-Year Experience of Coronary Endarterectomy for the Diffusely Diseased Left Anterior Descending Artery.

Kosaku Nishigawa1, Toshihiro Fukui2, Masataka Yamazaki2, Shuichiro Takanashi2.   

Abstract

BACKGROUND: Coronary endarterectomy (CE) is a surgical option for a diffusely diseased coronary artery. This study evaluated the clinical and angiographic outcomes of CE for a diffusely diseased left anterior descending artery (LAD) using the internal thoracic artery (ITA).
METHODS: From September 2004 to September 2014, 188 patients (163 men; mean age, 66.1 years) underwent coronary artery bypass grafting with CE for a diffusely diseased LAD. Forty patients (21.3%) had unstable angina, and 55 (29.3%) were at Canadian Cardiovascular Society class 3 or 4. Mean ejection fraction was 0.55. Endarterectomy was performed under direct vision through a long arteriotomy in all patients. Angiographic evaluation was performed before discharge and at 1 year after the operation.
RESULTS: Mean arteriotomy length was 6.1 ± 1.8 cm. The endarterectomized LAD was reconstructed using the left ITA in 179 (95.2%) or the right ITA in 9 (4.8%). The operation was conducted off pump in 185 patients (98.4%). The 30-day mortality was 1.1%. Perioperative myocardial infarction occurred in 17 patients (9.0%). The patency rate of the ITA and LAD at early postoperative and follow-up angiography was 91.6% and 96.6%, respectively. Optical coherence tomography performed in 8 patients revealed that the endarterectomized LAD was completely endothelialized and that the surface of the reconstructed lumen had become homogeneous within 1 year after the operation. The median follow-up period was 5.8 years. At 5 years, freedom from all-cause death was 89.3% ± 2.4% and freedom from major adverse cardiac and cerebrovascular events was 74.0% ± 3.3%.
CONCLUSIONS: CE for a diffusely diseased LAD using the ITA provides satisfactory clinical outcomes with favorable rates of angiographic patency.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28168963     DOI: 10.1016/j.athoracsur.2016.11.028

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Segmental clamp and distal perfusion technique for reducing myocardial ischemia during coronary onlay grafting on a beating heart.

Authors:  Naoki Minato; Takayuki Okada; Shinya Kanemoto; Nobuya Zempo
Journal:  Surg Today       Date:  2018-01-09       Impact factor: 2.549

2.  Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.

Authors:  Hua Yan; Xieraili Tiemuerniyazi; Yangwu Song; Fei Xu; Wei Feng
Journal:  J Cardiothorac Surg       Date:  2020-06-29       Impact factor: 1.637

3.  Coronary Endarterectomy: a Case Control Study and Evaluation of Early Patency Rate of Endarterectomized Arteries.

Authors:  Mario Augusto Cray da Costa; André Luís Betero; Jefferson Okamoto; Marcelo Schafranski; Elise Souza Dos Reis; Ricardo Zanetti Gomes
Journal:  Braz J Cardiovasc Surg       Date:  2020-02-01

4.  Coronary endarterectomy for diffusely diseased coronary artery: An ace in the hole in coronary artery surgery.

Authors:  Kosaku Nishigawa; Toshihiro Fukui; Jun Takaki; Shuichiro Takanashi
Journal:  JTCVS Tech       Date:  2021-03-21

5.  Mid-term outcomes of coronary endarterectomy combined with coronary artery bypass grafting.

Authors:  Xieraili Tiemuerniyazi; Hua Yan; Yangwu Song; Yifeng Nan; Fei Xu; Wei Feng
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-22

6.  Coronary endarterectomy: an old tool for patients currently operated on with coronary artery bypass grafting. Long-term results, risk factor analysis.

Authors:  Paolo Nardi; Marco Russo; Guglielmo Saitto; Emanuele Bovio; Sara Rita Vacirca; Carlo Bassano; Antonio Scafuri; Antonio Pellegrino; Giovanni Ruvolo
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.